alphaveZIMLAB₹137.20

Zim Laboratories Limited

₹ CrorePeersANUHPHR VALIANTLAB AHCL ALBERTDAVD WANBURY HALEOSLABS BAJAJHCARE THEMISMEDMcap ₹734 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Total Debt	106.4	112.2	123.0	123.0
Net Debt	96.8	110.2	97.9	97.9
Total Debt/Equity	0.45	0.44	0.42	0.42
Net Debt/Equity	0.41	0.44	0.33	0.33
Total Debt/EBITDA	2.57	2.57	4.10	4.10
Net Debt/EBITDA	2.34	2.52	3.26	3.47
Interest Coverage (EBIT/Interest)	3.67	2.07	0.76	0.76
Total Debt/Total Capital %	30.82	30.78	29.34	29.34
As Filed — company-reported covenants
Debt/Equity (as filed)	—	0.44	0.42	0.50
Debt Service Coverage (as filed)	2.00	1.65	1.13	0.53
Interest Service Coverage (as filed)	4.00	2.58	1.62	-0.53

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.